Last Updated:
First Published:
Merck on Tuesday revealed a lower-than-expected outlook for 2026 as the drugmaker aims to remake its business before its powerhouse cancer drug loses patent protection in a few years.
The stock
MRK closed 2% higher at $115.83 on Tuesday after Merck said expects $65.5 billion and $67.0 billion in revenue for the year, which is slightly lower than the FactSet estimate of $67.4 billion. It had $65.0 billion in revenue in 2025. The stock had closed Monday at a 16-month high.
